Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.54 |
| ▸ | RARB | P10826 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.51 |
| ▸ | TPH1 | P17752 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993787 | 1.00 | SLC7A5 (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL28381546 | 0.98 | S1PR2 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2779653 | 0.95 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL6771201 | 0.95 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2779651 | 0.95 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL180335 | 0.90 | RARB (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL28653399 | 0.88 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2496326 | 0.88 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL18112674 | 0.88 | KCNH2 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL5460504 | 0.85 | S1PR1 (0.68) | S1PR2S1PR1ALDH1A1S1PR3SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118339289-A | Transfer RNA composition and use in the production of proteins containing non-standard amino acids | 艾伯赛公司 | 2024-07-12 | — | — | CN | claimed |
| CN-111655726-B | Antifolate receptor alpha antibody conjugates and uses thereof | 苏特罗生物制药公司 | 2024-06-21 | — | — | CN | claimed |
| EP-4382124-A2 | METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION | Ambrx, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-06-06 | — | — | US | claimed |
| US-20240167044-A1 | METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION | AMBRX, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-20240148890-A1 | ANTI-FOLATE RECEPTOR CONJUGATE THERAPY FOR CANCER TREATMENT | FRED HUTCHINSON CANCER CENTER | 2024-05-09 | — | — | US | claimed |
| US-11958909-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2024-04-16 | — | — | US | claimed |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2024-03-14 | — | — | US | claimed |
| US-11919934-B2 | IL-15 conjugates and uses thereof | Synthorx, Inc. (US) | 2024-03-05 | — | — | US | claimed |
| CN-117651565-A | Combination therapy with antifolate receptor conjugates and bevacizumab | 苏特罗生物制药公司 | 2024-03-05 | — | — | CN | claimed |
| WO-2006132969-A2 | INCORPORATION OF NON-NATURALLY ENCODED AMINO ACIDS INTO PROTEINS | AMBRX, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060063244-A1 | Comprises ribonuclease barnase marker gene; libraries; drug resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-03-23 | — | — | US | claimed |
| US-20050287639-A1 | Methods of incorporating amino acid analogs into proteins | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-12-29 | — | — | US | claimed |
| US-20050250183-A1 | In vivo incorporation of unnatural amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-11-10 | — | — | US | claimed |
| US-20050208536-A1 | Comprises ribonuclease barnase marker gene; libraries; drug resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-09-22 | — | — | US | claimed |
| US-20050009049-A1 | Expanding the eukaryotic genetic code | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-01-13 | — | — | US | claimed |
| EP-1490483-A2 | IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | The Scripps Research Institute (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030108885-A1 | Comprises ribonuclease barnase marker gene; recombination/genetic engineering; libraries; drug resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-06-12 | — | — | US | claimed |
| US-20030082575-A1 | Translation system for use in the generation of protein containing adjusted amino acid sequences | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-05-01 | — | — | US | claimed |
| WO-2002085923-A2 | IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050287639-A1 | Methods of incorporating amino acid analogs into proteins | AARS1, GARS1, NSUN3 | SLC7A5 58/4885ALPI 3904/4885PKM 4005/4885 |
| US-20050250183-A1 | In vivo incorporation of unnatural amino acids | BCAT1, AADAT, NPEPPS | SLC7A5 16/4885ALPI 1515/4885PKM 2702/4885 |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | SLC7A5 1836/4885ALPI 506/4885PKM 3270/4885 |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | SLC7A5 2691/4885ALPI 1470/4885PKM 4766/4885 |
| US-20050009049-A1 | Expanding the eukaryotic genetic code | NSUN3, AARS1, TRMT1 | SLC7A5 263/4885ALPI 4175/4885PKM 3536/4885 |
| US-11958909-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | DNPEP, LNPEP, ANPEP | SLC7A5 310/4885ALPI 3351/4885PKM 4505/4885 |
| US-20050208536-A1 | Comprises ribonuclease barnase marker gene; libraries; drug resistance | RNASEL, RNASEH1, RNASE1 | SLC7A5 871/4885ALPI 2777/4885PKM 4119/4885 |
| US-20240148890-A1 | ANTI-FOLATE RECEPTOR CONJUGATE THERAPY FOR CANCER TREATMENT | FOLR1, FOLR2, FOLH1 | SLC7A5 966/4885ALPI 4519/4885PKM 4265/4885 |
| US-20030108885-A1 | Comprises ribonuclease barnase marker gene; recombination/genetic engineering; libraries; drug resistance | RNASEL, RNASEH1, RNASE1 | SLC7A5 1537/4885ALPI 2719/4885PKM 3957/4885 |
| US-11919934-B2 | IL-15 conjugates and uses thereof | IL15, IL15RA, IL2 | SLC7A5 757/4885ALPI 1117/4885PKM 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.